secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001193125-23-226903
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm adds Dr. Zhen Su as independent director; board expands to nine
--------------------------------------------------------------------------

- Board increased to nine members; Dr. Su elected as Class III director, term through 2025 annual meeting.
- Dr. Su receives option for 68,000 shares at $1.28 (closing price on grant date), vesting over three years.
- Cash retainer of $50,000 for board service plus $10,000 for committee, prorated from effective date.
- Standard indemnification agreement and no related-party transactions requiring disclosure.
- Appointed to Commercialization and Portfolio Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523226903/0001193125-23-226903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523226903/d539927d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-226903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer